Genetically engineered nk cells and uses thereof

CN122168647APending Publication Date: 2026-06-09IMMUXELL BIOTECH LTD
View PDF 1 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
IMMUXELL BIOTECH LTD
Filing Date
2024-12-06
Publication Date
2026-06-09

AI Technical Summary

Technical Problem

In current tumor immunotherapy, tumor cells escape TCR-T therapy by downregulating MHC class I molecules, resulting in poor treatment efficacy. CAR-NK cells can only recognize surface antigens and cannot recognize internal antigens, leading to unsatisfactory results in solid tumors.

Method used

By transducing the TCR-CD8α-CD3 complex onto the surface of NK cells, specific recognition of tumor cells can be achieved while retaining the killing effect of MHC class I molecules downregulating tumor cells. Nucleic acid constructs of TCR, CD8α, and CD3 are introduced into NK cells using a retroviral vector.

Benefits of technology

The prepared 051TCR-NK genetically engineered cells exhibit significant cytotoxicity against HLA-A*11:01 KRAS G12V mutant cells, and can specifically recognize and kill KRAS G12V mutant tumor cells, making them suitable for clinical treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0005178408320000011
    Figure HDA0005178408320000011
  • Figure HDA0005178408320000021
    Figure HDA0005178408320000021
  • Figure HDA0005178408320000022
    Figure HDA0005178408320000022
Patent Text Reader

Abstract

The present invention relates to genetically engineered NK cells and uses thereof. Specifically provided is a host cell comprising a nucleic acid construct comprising (1) a nucleotide sequence encoding a TCR and a CD8a molecule and (2) a nucleotide sequence encoding a CD3 molecule. The cells produced by the present invention have significant cytotoxicity against specific tumor cells and retain the killing effect of NK cells on tumor cells with down-regulated MHC class I molecules.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • T cell receptor targeting KRAS g12v mutant polypeptide, and use thereof

    WO2023241522A1